TY - JOUR
T1 - Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer
AU - Zhang, Changhua
AU - Awasthi, Niranjan
AU - Schwarz, Margaret A.
AU - Schwarz, Roderich E.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/6/15
Y1 - 2013/6/15
N2 - Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P < 0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.
AB - Background: Peritoneal dissemination of gastric cancer is a common reason for unresectability, a frequent recurrence mechanism, and a common cause for death. The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses. Materials and methods: Human gastric cancer cell lines AGS, NCI-N87, and SNU-16 were intraperitoneally injected into nude mice and severe combined immunodeficiency (SCID) mice. The peritoneal tumor formation and mouse survival were compared among different groups. Mice were treated with oxaliplatin (5 mg/kg) and NVP-BEZ235 (10 mg/kg). Results: The formation rate of peritoneal cancer after intraperitoneal injection of 5 × 106 SNU16, NCI-N87, and AGS cells was 2/8, 6/8, and 0/8 in nude mice, and 6/6, 6/6, and 0/6 in SCID mice, respectively. Median animal survival with peritoneal dissemination was 74 d for NCI-N87 cells (10 × 106), 95 d for SNU16 cells (10 × 106), 78 d for SNU16 cells (20 × 106), and 44 d for SNU16 cells (40 × 106). In a therapeutic experiment with 40 × 106 SNU16 cells, animal survival was significantly improved by oxaliplatin treatment compared with the control group (58.5 d versus 45 d, P < 0.001), but not by NVP-BEZ235 (48 d versus 45 d, P = 0.249) treatment. In the accompanying subcutaneous SNU16 mouse model, relative tumor volume compared with controls was not significantly decreased by oxaliplatin treatment (P = 0.151) but by NVP-BEZ235 therapy (P = 0.008). Conclusions: Peritoneal gastric cancer xenografts were successfully established after intraperitoneal injection NCI-N87 and SNU16 cells. These findings provide a useful survival outcome assessment model for experimental gastric cancer research.
KW - Gastric cancer
KW - Mouse model
KW - Peritoneal dissemination
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84877718320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877718320&partnerID=8YFLogxK
U2 - 10.1016/j.jss.2012.10.052
DO - 10.1016/j.jss.2012.10.052
M3 - Article
C2 - 23201270
AN - SCOPUS:84877718320
SN - 0022-4804
VL - 182
SP - 227
EP - 234
JO - Journal of Surgical Research
JF - Journal of Surgical Research
IS - 2
ER -